 (Gut 1993; 34: 958-962) 
The treatment of choice for rectal and rectosigmoid cancer is complete surgical resection. Unfortunately many patients present with tumours too extensive to resect or they are unfit for such surgery. The proportion of patients in this group varies between studies but is over 10%.' 2 A further group with anastomotic recurrences are often unsuitable for further surgery. Palliative resection carries a high morbidity and a mortality of 10-30%. ' Eleven of these patients had rectal or rectosigmoid adenocarcinoma (including one with cancerous change in a villous adenoma), one had direct rectal invasion from cervical cancer, and one an extensive villous adenoma (with no documented focus of adenocarcinoma). Eleven were considered unfit for surgery including three with metastases and three recurrences after surgery, two of whom had rectal stump recurrences after abdominoperineal resections. The other two tumours were unresectable at laparotomy. The tumour length was 2-14 cm (median 5 cm) and the lower margin of the tumour was at 0-14 cm (median 6 cm) from the anal verge. At least six patients with lesions less than 7 cm from the anal margin would have required permanent colostomy if palliative resection had been carried out. Eight patients had circumferential lesions (C3) and five had 1/3-2/3 circumferential lesions (C2). risk of obstruction) were not given a further follow up appointment. Those with tumour regrowth requiring laser energy ofaround 5000 J or more and those with a stricture that would not immediately allow passage of an endoscope were given a follow up appointment at four to six weeks for repeat laser endoscopy. This was essential because if there is a possibility of obstruction developing it is inappropriate in this patient group to wait for symptoms to develop. Inevitably, follow up appointments were given to some extent on a subjective basis according to the laser endoscopist's previous experience. As all these procedures were carried out by two endoscopists (IRS and SGB) we do not consider that this led to significant bias. All patients were subsequently contacted monthly by the research nurse (ST) to document progress and assess the necessity for further treatment. Patients were evaluated according to endoscopic result, early and late functional success, necessity for repeat endoscopic treatment, and dose rate of laser energy required to control intraluminal tumour (averaged laser energy per month).
STATISTICAL METHODS
Paired data for laser energy per month required and for frequency of endoscopic treatment before and after radiotherapy were analysed with the Wilcoxon signed rank test. Table I gives a summary of the results for endoscopic and symptomatic success. TREATMENT REQUIREMENTS Whenever possible laser and radiotherapy were performed on an outpatient basis although many patients came from long distances so radiotherapy had to be given as an inpatient. Days in hospital ranged from nil to 52 (median 20 days). Overall the number of laser treatments required ranged from zero to 20 (median five). The number before radiotherapy was one to nine (median two) and after radiotherapy nil to 11 (median three). Table II shows the laser treatment intervals required to control symptoms. The treatment intervals before radiotherapy are given for the patients who were followed up for three months or more while undergoing laser treatment. This period was chosen as we considered that it was the minimum required to obtain a good baseline for treatment frequency and laser energy requirements for good tumour control. The initial treatment intervals start from the time of completion of the initial recanalisation, whether this took one or more treatments. Some patients were brought back routinely four weeks after recanalisation and most four to eight weeks after radiotherapy. The routine checks distort the data to some extent but because checks were performed both before and after radiotherapy the bias is minimised. The figures show a dramatic increase in treatment interval from four weeks before treatment to 20 weeks after, the treatment interval for C2 tumours being longer than that for C3 (p<0-01). In terms of laser energy required to control symptoms (excluding initial recanalisation (Table III) 
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